Invea Therapeutics (INAI) files for proposed IPO

Invea Therapeutics (INAI) has filed for a proposed Nasdaq IPO.

The company describes itself as: "We are a biotechnology company seeking to develop oral, small-molecule therapies for immune-mediated inflammatory diseases, or IMIDs. IMIDs are a diverse group of conditions — including skin or cutaneous inflammatory diseases such as chronic urticaria (commonly known as hives), atopic dermatitis, and prurigo nodularis; joint or rheumatologic and connective tissue disorders, such as rheumatoid arthritis and systemic lupus erythematosus; gut or gastrointestinal diseases, such as inflammatory bowel disease, including Crohn’s disease and ulcerative colitis; lung or respiratory and allergic airway conditions, such as asthma and allergic rhinitis; and autoimmune neurological diseases such as multiple sclerosis — that could result from an imbalanced or dysregulated immune response leading to chronic, multi-system or organ inflammation. Current treatments are often injectable biologics or broad immunosuppressants with safety, convenience and/or cost limitations. Our goal is to develop safe, effective, and convenient oral small molecule therapies that not only reduce inflammation, but also enhance quality of life, and potentially help achieve long-term disease remission."

ThinkEquity will serve as sole underwriter.

You May Also Be Interested In

• Sinda Ltd. files for 17.75M share PO at $11.25-$13.25/sh
• Qualcomm targets $40B in non-handset revenue by fiscal 2029
• Spruce Power director Ja-chin Audrey Lee resigns from board